BSE: APLLTD - Alembic Pharmaceuticals Limited

Yield per half year: -29.58%
Dividend yield: +0.87%

Alembic Pharmaceuticals Limited

Underestimation

Parameter Grade Value Sector average Difference with sector, % Average for 5 years Difference from average, %
P/E
6/10
24.69 45.74 -46.03% 23.87 +3.42%
P/S 2.49 5.12 -51.46%
P/BV 3.16 6.3 -49.92%
P/FCF 28.6 168.72 -83.05%
Ev/Ebitda 17.77 13.54 31.23%
Ev/S 2.54 4.77 -46.76%
Ev/FCF 32.61 163.7 -80.08%
E/P 0.0453 0.0451 0.4161%

Efficiency

Parameter Grade Value Sector average Difference with sector, % Average for 5 years Difference from average, %
Ebitda margin
4/10
11.13 20.29 -45.16% 16.37 -32.03%
ROE 12.78 17.11 -25.32%
ROA 9.55 10.34 -7.56%
ROIC 0 10.89 -100%
ROS 10.08 11.98 -15.87%
ROCE 0 4.26 -100%

Debt

Parameter Grade Value Sector average Difference with sector, % Average for 5 years Difference from average, %
Debt/Ebitda
8/10
1.06 1.22 -12.85% 0.953 +11.41%
Nеt Debt/Ebitda 0.4562 1.06 -56.9%
Debt/Ratio 0.112 0.1307 -14.3%
Debt/Equity 0.2407 0.7972 -69.81%
Debt/Net Income 1.17 3.19 -63.27%

Dividends

Parameter Grade Value Sector average Difference with sector, % Average for 5 years Difference from average, %
Dividend yield
2.18/10
0.8659 11.92 -92.74% 1.52 -42.91%
Number of years of dividend growth 0 1.26 -100%
DSI 0.8571 0.8481 1.06%
Average dividend growth 15.58 -63.67 -124.47%
Average percentage for 5 years 1.52 11.6 -86.93%
Average percentage for payments 27.66 30.57 -9.53%
Difference from average difference in sector -11.06

Growth impulse

Parameter Grade Value Sector average Difference with sector, %
Growth impulse Revenue in 5 years
5/10
32.71 80.84 -59.54%
Growth impulse Ebitda in 5 years -41.82 45.31 -192.3%
Growth impulse Net Income in 5 years -25.7 131.41 -119.56%
Growth impulse FCF in 5 years -266.47 76.02 -450.53%
Growth impulse EPS in 5 years -18.89 286.48 -106.59%
IP Score
4.67/10

Similar companies

Biocon Limited

Aurobindo Pharma Limited

Torrent Pharmaceuticals Limited

Cipla Limited

Pay for your subscription

More functionality and data for company and portfolio analysis is available by subscription